Continuous infusion of ketamine for adjunctive analgosedation in mechanically ventilated patients with chronic obstructive pulmonary disease

Murat Haliloğlu, Burcu İleri Fikri, Aybüke Kekeçoğlu, Mehmet Toptaş

Abstract:

BACKGROUND AND AIM: Ketamine is a fast-acting, hypnotic, amnestic agent that may be used to manage pain and agitation which is refractory to commonly used sedatives and analgesics. However, there is a paucity of literature describing the effects of continuous infusion of ketamine on sedative and analgesic consumption and delirium in mechanically ventilated patients. This investigation describes a single institution's use of ketamine infusions as a part of a sedation protocol in the respiratory intensive care unit (RICU).

METHODS: This was a retrospective cohort study of mechanically ventilated patients with chronic obstructive pulmonary disease (COPD) who received ketamine infusions as a part of a sedation protocol in a 16-bed RICU. The patients have assessed sedative consumption, analgesic consumption, and delirium incidence.

RESULTS: A total of 100 COPD patients receiving ketamine continuous infusion as a part of a sedation protocol between November 2017 and April 2020 were eligible and enrolled in this study. We found that patients had a reduction in opioid and benzodiazepine requirements at 24, 48, and 72 h after ketamine initiation (p<0.05). In addition, significant reductions in vasopressor requirements were observed at 24, 48, and 72 h after ketamine initiation (p<0.05). During the analyzed time frame, all patients received ketamine infusion at 4 μg/kg/min. There were no reported adverse drug reactions.

CONCLUSIONS: In this cohort of COPD patients who required mechanical ventilation we found decreased benzodiazepine, opiate, and vasopressor doses when the addition of a ketamine infusion, with no adverse drug reactions. Further prospective research is warranted to define optimal dosing strategies.

Keywords:

COPD, ketamine, mechanical ventilation, sedation
Introduction

The appropriate sedation and analgesia of mechanically ventilated patients to manage their anxiety, decrease excessive oxygen consumption, and facilitate care can be challenging. Although commonly used sedatives and analgesics are effective for many patients, they are associated with numerous side effects including opioid-induced constipation and hemodynamic instability associated with propofol and dexmedetomidine.\(^\text{[1,2]}\) Furthermore, the administration of opiates alone or in combination with benzodiazepines has been identified as a risk factor for delirium, which involves changes in consciousness, attention, cognition, and perception.\(^\text{[3,4]}\)

Ketamine, a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, provides sedation, amnesia, and analgesia and also maintains pulmonary compliance while reducing airway resistance.\(^\text{[5–7]}\) Therefore, ketamine offers an additional option for sedation in mechanically ventilated patients with chronic obstructive pulmonary disease (COPD).

The pharmacological profile of ketamine makes it an appealing sedative, but literature evaluating its effect on traditional agents (e.g., fentanyl and midazolam) in mechanically ventilated patients is limited. In this study, we postulated that continuous infusion of ketamine may decrease sedative and analgesic consumption and also delirium incidence in mechanically ventilated patients with COPD.

Materials and Methods

Study design and settings

This is a single-center observational retrospective study in our 16-bed respiratory intensive care unit (RICU) which receives about 600–650 inpatients/year. The study protocol was reviewed and approved by the local Institutional Ethical Board (approval number 2021-134 and date July 1, 2021). This study was carried out in accordance with the Helsinki Declaration.

Our unit follows an institutional physician-driven protocol based on targeting the sedation status to Richmond Agitation Sedation Scale scores of −2 to +1.\(^\text{[8]}\) The protocol includes a first line sedation strategy using a continuous infusion of either an opioid (fentanyl, starting dose 0.7 \(\mu\)g/kg/h), a benzodiazepine (midazolam, starting dose 0.03 mg/kg/h), or more frequently, a combination of both, based on patients’ clinical characteristics and their expected trajectory of illness. In the case of suboptimal analgesedation despite the use of high dosages of opioids and benzodiazepines, a second line analgesedation agent received a continuous infusion of ketamine at the dose of 4 \(\mu\)g/kg/min. The onset of delirium was monitored each day using the confusion assessment method for the ICU (CAM-ICU) by bedside nurses.\(^\text{[9]}\)

Study population

We included all mechanically ventilated patients with COPD who received ketamine infusions for 24 h or longer between November 2017 and April 2020. Patients who were pregnant or in lactation, who had psychosis as defined by the Diagnostic and Statistical Manual of Mental Disorders-IV, who received concomitant neuromuscular blockers, who showed chronic use of opiates, and who started on ketamine on day 1 of mechanical ventilation were excluded from the study.

Data collection

All data from this study were obtained by retrospective querying of the institutional electronic system and medical charts. The following variables were collected: (1) demographic characteristics, age, sex, and weight; (2) clinical baseline features including comorbidities, the Acute Physiologic and Chronic Health Evaluation (APACHE) II score, the Sequential Organ Failure Assessment (SOFA) score; (3) characteristics of ICU stay, including length of MV, length of ICU stay, 28-day mortality, and 90-day mortality; (4) type and dosages of concomitant continuous infusions of analgesics, sedative, and vasopressor drugs in 72 h before and after initiation of ketamine infusion; (5) cases of withdrawal syndrome and delirium throughout ICU stay; and (6) all adverse events (AEs) with onset during the ketamine infusion.

Outcome measures

For our study, when used as an adjuvant for difficult sedation, ketamine was considered effective if no increases in the dosages of other analgesics and sedatives had been necessary within the 72 h of ketamine infusion. Finally, the ketamine safety profile was evaluated as a secondary endpoint, with particular attention to hypertension, tachycardia, laryngospasm, hypersalivation, emesis, nystagmus, anaphylaxis, and erythema.
**Statistical analysis**

The data were analyzed using the Statistical Package for the Social Sciences for Windows version 26.0 software package (SPSS, Chicago, IL, USA). Normality of distribution was assessed using the Shapiro–Wilk test. Quantitative variables have been expressed as mean±standard deviation and median [Interquartile Range]. The hemodynamic properties, sedative usage, analgesic usage, and vasopressor usage between pre- and post-ketamine infusion were assessed by the Wilcoxon signed-rank test. P<0.05 was considered statistically significant.

**Results**

During the evaluation period, we identified 135 mechanically ventilated COPD patients who met the inclusion criteria. Twenty-eight patients were excluded for concomitant neuromuscular blocker therapy, 5 patients were excluded for receiving ketamine infusion for less than 24 h, and 2 patients did not have complete documentation. Of the 100 patients included in the analysis, the majority of patients were male, with 65.1±13.4 years (Table 1).

Adjunctive analgesics and sedatives were reduced without the initiation of alternative sedatives. Daily consumption of fentanyl was significantly reduced 24 h [2.25±1.56 vs 1.71±1.56 µg/kg/h (p<0.001)], 48 h [2.25±1.56 vs 1.20±1.62 µg/kg/h (p<0.001)], and 72 h [2.25±1.56 vs 0.52±1.11 µg/kg/h (p<0.001)] after ketamine was introduced (Table 2). Compared with pre-ketamine initiation, the midazolam dose also was lower at 24 h [0.21±0.71 vs 0.14±0.59 mg/kg/h (p=0.007)], 48 h [0.21±0.71 vs 0.10±0.47 mg/kg/h (p<0.001)], and 72 h [0.21±0.71 vs 0.13±0.58 mg/kg/h (p<0.001)] (Table 2).

Hemodynamic parameters of the patients are presented in Table 2. During the analyzed time frame, heart rate and blood pressure did not change significantly. Sixty-five patients in our cohort needs vasopressor support, 19 patients continued on the vasopressor support, and 46 had vasopressors discontinued. The dose of norepinephrine was significantly reduced after ketamine initiation at 24 h [0.12±0.18 vs 0.09±0.14 µg/kg/min (p<0.001)], 48 h [0.12±0.18 vs 0.06±0.17 µg/kg/min (p<0.001)], and 72 h [0.12±0.18 vs 0.06±0.2 µg/kg/min (p<0.001)] (Table 3).

During the analyzed time frame, all patients received ketamine infusion at 4 µg/kg/min. The incidence of an AE in our patient population possibly attributed to ketamine was also reviewed. There were no reported AEs. Also, none of the patients developed hypersalivation requiring the use of atropine.

Delirium in ICU is associated with diagnostic challenges because the patient was unable to participate in the CAM-ICU evaluation. Twelve (12%) patients tested positive for delirium during their ICU stay.

**Discussion**

In this study, patients received significantly lower doses of benzodiazepine, opiate, and vasopressor dose when ketamine was initiated as a part of a multidrug sedation regimen, with no adverse reactions. To our knowledge, this is the first study to show the benefits of low-dose ketamine infusion in mechanically ventilated COPD patients.

---

**Table 1: Baseline characteristics and treatment outcomes of patients**

| Variable                          | All patients (n=100) |
|-----------------------------------|---------------------|
|                                  | n                  | %       |
| Age (years)                      | 65.1±13.4          |
| Body mass index                  |                     |
| Underweight                      | 3                  | 3       |
| Normal                           | 44                 | 44      |
| Overweight                       | 35                 | 35      |
| Obese                            | 17                 | 17      |
| Morbid obese                     | 1                  | 1       |
| Comorbidities                    |                     |
| Hypertension                     | 35                 | 35      |
| Diabetes                         | 14                 | 14      |
| CHF                              | 30                 | 30      |
| CKD                              | 12                 | 12      |
| APACHE II score                  | 26.3±7.6           |
| SOFA score at ICU admission      | 7.2±2.9            |
| Creat Cl (mL/min)                | 79.6±35.9          |
| Vasopressor used                 | 34                 | 34      |
| Mechanical ventilation length, median [IQR] (days) | 11 [6–18]          |
| ICU length of stay               | 18.6±12.8          |
| Delirium status                  | 12                 | 12      |
| 28-day mortality                 | 38                 | 38      |
| 90-day mortality                 | 41                 | 41      |

Data presented as mean±standard deviation unless otherwise indicated. Body mass index is classified as underweight (<18.5 kg/m²), normal weight (18.5–24.9 kg/m²), overweight (25–29.9 kg/m²), obese (30–39.9 kg/m²), and morbid obese (>40 kg/m²). CHF: Congestive heart failure, CKD: Chronic kidney diseases, APACHE II: Acute Physiology and Chronic Health Evaluation II, SOFA: Sequential Organ Failure Assessment, ICU: Intensive care unit, Creat Cl: Creatinine clearance, IQR: Interquartile range
Achieving and maintaining adequate analgesia before sedation has been shown to decrease the duration of mechanical ventilation which is typically achieved by the use of opioids. The opioid-sparing effect of ketamine was observed in our cohort patients. Our finding is consistent with previous works of literature examining low-dose ketamine.\textsuperscript{[10–13]} Ketamine is an agonist of the $\mu$-, $\delta$-, $\kappa$-opioid receptors and an antagonist of NMDA, which may explain the reduction in opioid consumption.\textsuperscript{[14,15]}

Our study demonstrated that the use of ketamine infusion in mechanically ventilated patients reduced not only opioid consumption but also the use of benzodiazepine without compromising adequate sedation. The benzodiazepine sparing effects of ketamine are consistent with the existing literature targeting light sedation strategy despite that none have evaluated its use in describing deep sedation.\textsuperscript{[16,17]} This is important because continuous infusions of benzodiazepines for a prolonged time are related to delirium, long-term cognitive dysfunction, and a longer duration of mechanical ventilation.\textsuperscript{[16,19]}

In addition to its favorable respiratory dynamics profile, ketamine may have a chronotropic effect on the cardiovascular system, mediated by the sympathetic nervous system.\textsuperscript{[14]} We observed a significant reduction in vasopressor requirement in our cohort of patients. This is consistent with what has been reported in the literature when low-dose ketamine is used for light sedation in mechanically ventilated adult patients.\textsuperscript{[11]}

Delirium in critically ill patients is important as it is associated with diagnostic challenges and therapeutic dilemmas, and each additional day of delirium is associated with a 10\% increased risk of death.\textsuperscript{[20,21]} Currently, dexmedetomidine appears to show promising results, but it is an expensive molecule that may be associated with numerous side effects like bradycardia, hypotension, hypertension, nausea, and atrial fibrillation.\textsuperscript{[22,23]} Also, several studies suggest that due to immune-regulatory properties in the peripheral and central nervous system, ketamine can be used for the treatment of delirium and depression.\textsuperscript{[24,25]} Using the CAM-ICU, 12 patients (12\%) were tested positive for delirium during their ICU stay. This was much lower than expected, as the incidence of delirium in mechanically ventilated patients admitted to the RICU had been reported to be as high as 24.4\%.

Recent studies have suggested that ketamine has been associated with both the proconvulsant and anticonvulsant effects.\textsuperscript{[26]} In this study, the seizure was not observed in any patients receiving ketamine. Additionally, ketamine

\begin{table}[h]
\centering
\caption{Continuous infusion analgesic and sedative dose requirements before and after ketamine initiation}
\begin{tabular}{|c|c|c|c|c|}
\hline
Drug & Before ketamine & 24 h after ketamine & 48 h after ketamine & 72 h after ketamine \\
& Initiation & initiation & initiation & initiation \\
\hline
Ketamine, n & 0 & 100 & 100 & 100 \\
Dose (µg/kg/min) & 100 & 4 & 4 & 4 \\
Fentanyl, n & 2.25±1.56 & 1.71±1.56 & 1.20±1.62 & 0.52±1.11 \\
& 100 & 77 & 51 & 27 \\
Dose (µg/kg/h) & 0.21±0.71 & 0.14±0.59 & 0.10±0.47 & 0.13±0.58 \\
Midazolam, n & 0.12±0.18 & 0.09±0.14 & 0.06±0.17 & 0.06±0.2 \\
& 65 & 60 & 34 & 19 \\
Dose (mg/kg/min) & 81 & 116.00±21.63 & 106.48±41.86 & 90.85±58.05 \\
& 6.1±13.78 & 52.57±21.06 & 50.56±28.44 & 58.15±11.7 \\
DBP (mmHg) & 91.76±24.49 & 86.09±15.63 & 79±35.53 & 68±44.03 \\
& 65 & 60 & 34 & 19 \\
HR (beats/min) & 0.12±0.18 & 0.09±0.14 & 0.06±0.17 & 0.06±0.2 \\
& 65 & 60 & 34 & 19 \\
Noradrenaline, n & 0.12±0.18 & 0.09±0.14 & 0.06±0.17 & 0.06±0.2 \\
& 65 & 60 & 34 & 19 \\
Dose (mg/kg/min) & 0.12±0.18 & 0.09±0.14 & 0.06±0.17 & 0.06±0.2 \\
& 65 & 60 & 34 & 19 \\
Fentanyl, n & 0.21±0.71 & 0.14±0.59 & 0.10±0.47 & 0.13±0.58 \\
& 65 & 60 & 34 & 19 \\
Dose (mg/kg/min) & 0.21±0.71 & 0.14±0.59 & 0.10±0.47 & 0.13±0.58 \\
& 65 & 60 & 34 & 19 \\
Midazolam, n & 0.21±0.71 & 0.14±0.59 & 0.10±0.47 & 0.13±0.58 \\
& 65 & 60 & 34 & 19 \\
Dose (mg/kg/min) & 0.21±0.71 & 0.14±0.59 & 0.10±0.47 & 0.13±0.58 \\
& 65 & 60 & 34 & 19 \\
\hline

Data presented as mean±standard deviation unless otherwise indicated. n represents the number of patients on continuous infusion. *P<0.05 as a comparison of dosing at each specified time point to the original dosing at the time of ketamine initiation.
\end{tabular}
\end{table}
use has been associated with hypersalivation which is often managed with glycopyrrolate or atropine. None of the patients received pharmacotherapy because of hypersalivation. Some studies noted potential adverse effects including hypertension and tachyarrhythmias, which were not noted in any of the patients while on ketamine. Ketamine infusion at lower doses (<10 μg/kg/min) does not seem to induce the psychomimetic side effects observed at higher doses.\[11\]

Our study has some limitations. The study was a single-center study and had a retrospective design, inability to manage interventions to influence analgesic and sedative requirements.

Conclusion

Despite these limitations, the current study highlights a favorable safety profile of low-dose ketamine without significant effects on hemodynamics or agitation. The initiation of ketamine infusion was associated with a significant decrease in overall fentanyl and midazolam requirements, suggesting a reasonable alternative for analgosedation in mechanically ventilated patients. However, prospective studies are needed to confirm these results and to determine the ideal dosing of ketamine in this setting.

Conflicts of interest

There are no conflicts of interest.

Ethics Committee Approval

The study was approved by the Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital Clinical Research Ethics Committee (No: 2021-134, Date: 01/07/2021).

Financial support and sponsorship

Nil.

Peer-review

Externally peer-reviewed.

Authorship Contributions

Concept – M.H., M.T.; Design – M.H., B.İ.F., A.K.; Supervision – M.H.; Funding – M.H.; Materials – None; Data collection &/or processing – B.İ.F., A.K.; Analysis and/or interpretation – M.H., B.İ.F., A.K., M.T.; Literature search – M.H., B.İ.F.; Writing – M.H., B.İ.F., A.K., M.T.; Critical review – M.H., M.T.

References

1. Devlin JW, Skrobik Y, Gélinas C, Needham DM, Slooter AJC, Pandharipande PP, et al. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Crit Care Med 2018;46:e925–73.
2. Riker RR, Fraser GL. Adverse events associated with sedatives, analgesics, and other drugs that provide patient comfort in the intensive care unit. Pharmacotherapy 2005;25:85–188.
3. Duprey MS, Dijkstra-Kersten SMA, Zaal IJ, Briesacher BA, Saczynski JS, Griffith JL, et al. Opioid use increases the risk of delirium in critically ill adults independently of pain. Am J Respir Crit Care Med 2021;204:566–72.
4. Psani MA, Murphy TE, Araujo KL, Slattum P, Van Ness PH, Inouye SK. Benzodiazepine and opioid use and the duration of intensive care unit delirium in an older population. Crit Care Med 2009;37:177–83.
5. Miller AC, Jamin CT, Elamin EM. Continuous intravenous infusion of ketamine for maintenance sedation. Minerva Anestesiol 2011;77:812–20.
6. Kolenda H, Gremmelt A, Rading S, Braun U, Markakis E. Ketamine for analgosedative therapy in intensive care treatment of head-injured patients. Acta Neurochir (Wien) 1996;138:1193–9.
7. Eikermann M, Grosse-Sundrup M, Zaremba S, Henry ME, Bittner EA, Hoffmann U, et al. Ketamine activates breathing and abolishes the coupling between loss of consciousness and upper airway dilator muscle dysfunction. Anesthesiology 2012;116:35–46.
8. Sessler CN, Gosnell MS, Grap MJ, Brophy GM, O’Neal PV, Keane KA, et al. The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients. Am J Respir Crit Care Med 2002;166:1338–44.
9. Ely EW, Shintani A, Truman B, Speroff T, Gordon SM, Harrell FE Jr, et al. Delirium as a predictor of mortality in mechanically ventilated patients. JAMA 2004;291:1753–62.
10. Guillou N, Tanguy M, Seguin P, Branger B, Campion JP, Malléendant Y. The effects of small-dose ketamine on morphine consumption in surgical intensive care unit patients after major abdominal surgery. Anesth Analg 2003;97:843–7.
11. Buchheit JL, Yeh DD, Eikermann M, Lin H. Impact of low-dose ketamine on the usage of continuous opioid infusion for the treatment of pain in adult mechanically ventilated patients in surgical intensive care units. J Intensive Care Med 2019;34:646–51.
12. De Pinto M, Jelacic J, Edwards WT. Very-low-dose ketamine for the management of pain and sedation in the ICU. J Opioid Manag 2008;4:54–6.
13. Park GR, Manara AR, Mendel L, Bateman PE. Ketamine infusion. Its use as a sedative, inotrope and bronchodilator in a critically ill patient. Anaesthesia 1989;42:980–3.
14. Reich DL, Silvay G. Ketamine: an update on the first twenty-five years of clinical experience. Can J Anaesth 1989;36:186–97.
15. White PF, Way WL, Trevor AJ. Ketamine—its pharmacology and therapeutic uses. Anesthesiology 1982;56:119–36.
16. Manasco AT, Stephens RJ, Yaege LH, Roberts BW, Fuller BM. Ketamine sedation in mechanically ventilated patients: A systematic review and meta-analysis. J Crit Care 2020;56:80–8.
17. Groetzinger LM, Rivosecchi RM, Bain W, Bahr M, Chin K, McVerry BJ, Barbash I. Ketamine infusion for adjunct sedation in mechanically ventilated adults. Pharmacotherapy 2018;38:181–8.
18. Barr J, Fraser GL, Puntillo K, Ely EW, Gélinas C, Dasta JF, et al; American College of Critical Care Medicine. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med 2013;41:263–306.

19. Carson SS, Kress JP, Rodgers JE, Vinayak A, Campbell-Bright S, Levitt J, et al. A randomized trial of intermittent lorazepam versus propofol with daily interruption in mechanically ventilated patients. Crit Care Med 2006;34:1326–32.

20. Pisani MA, Kong SY, Kasl SV, Murphy TE, Araujo KL, Van Ness PH. Days of delirium are associated with 1-year mortality in an older intensive care unit population. Am J Respir Crit Care Med 2009;180:1092–7.

21. Salluh JI, Wang H, Schneider EB, Nagaraja N, Yenokyan G, Damluji A, et al. Outcome of delirium in critically ill patients: systematic review and meta-analysis. BMJ 2015;350:h2538.

22. Constantin JM, Momon A, Manzt J, Payen JF, De Jonghe B, Perbet S, et al. Efficacy and safety of sedation with dexmedetomidine in critical care patients: a meta-analysis of randomized controlled trials. Anaesth Crit Care Pain Med 2016;35:7–15.

23. Quintard H, Sztark F. Dexmedetomidine, a revolution for sedation in ICU? Anaesth Crit Care Pain Med 2016;35:5–6.

24. Perbet S, Verdonk F, Godet T, Jabaudon M, Chartier C, Cayot S, et al. Low doses of ketamine reduce delirium but not opiate consumption in mechanically ventilated and sedated ICU patients: A randomised double-blind control trial. Anaesth Crit Care Pain Med 2018;37:589–95.

25. Mion G, Villevieille T. Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings). CNS Neurosci Ther 2013;19:370–80.

26. Kim JH, Lee CK, Yu SH, Min BD, Chung CE, Kim DC. Ketamine-induced generalized convulsive seizure during procedural sedation. Arch Craniofac Surg 2021;22:119–21.

27. Craven R. Ketamine. Anaesthesia 2007;62 Suppl 1:48–53.